JPH06501469A - サイトケラチン断片の精製 - Google Patents
サイトケラチン断片の精製Info
- Publication number
- JPH06501469A JPH06501469A JP3516125A JP51612591A JPH06501469A JP H06501469 A JPH06501469 A JP H06501469A JP 3516125 A JP3516125 A JP 3516125A JP 51612591 A JP51612591 A JP 51612591A JP H06501469 A JPH06501469 A JP H06501469A
- Authority
- JP
- Japan
- Prior art keywords
- cytokeratin
- fragments
- mixture
- produced
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 title claims description 63
- 102000011782 Keratins Human genes 0.000 title claims description 58
- 108010076876 Keratins Proteins 0.000 title claims description 58
- 238000000746 purification Methods 0.000 title description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 241000699670 Mus sp. Species 0.000 claims description 10
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims description 9
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 claims description 9
- 108010066327 Keratin-18 Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 108090000317 Chymotrypsin Proteins 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108010070511 Keratin-8 Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 229960002376 chymotrypsin Drugs 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 5
- 108010066302 Keratin-19 Proteins 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 108010051815 Glutamyl endopeptidase Proteins 0.000 claims description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 230000000984 immunochemical effect Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000001902 propagating effect Effects 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 4
- 230000006862 enzymatic digestion Effects 0.000 claims 2
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 claims 1
- 102000057297 Pepsin A Human genes 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 229920001220 nitrocellulos Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000004807 localization Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 1
- 101710194922 Keratin, type II cytoskeletal 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (13)
- 1.調製SDS−PAGEにより上皮腫瘍細胞からサイトケラチンを精製し、サ イトケラチン8、18および19に対応するバンドをゲルから溶出することを含 む、サイトケラチン抗原/免疫原の再現性のある産生法であって、サイトケラチ ンを消化して10−50Kdのサイズ範囲の断片の混合物を産生することを特徴 とする、上記方法。
- 2.消化は酵素的に行われることを特徴とする、請求項1に記載の方法。
- 3.消化は、キモトリプシン、V8プロテアーゼ、ペプシンおよびTPCKトリ プシンよりなる群から選択される酵素により行われることを特徴とする、請求項 2に記載の方法。
- 4.サイトケラチンはキモトリプシン(40−60U/mg蛋白)で、酵素:サ イトケラチンの重量比が1:50から1:1000で酵素消化されることを特徴 とする、請求項3に記載の方法。
- 5.酵素消化の酵素:サイトケラチンの重量比は、サイトケラチン8については 1:400、サイトケラチン18については1:1000、そしてサイトケラチ ン19については1:75であることを特徴とする、請求項4に記載の方法。
- 6.消化は、BrCN、加水分解またはBNPS−スカトールで、化学的に行わ れることを特徴とする、請求項1に記載の方法。
- 7.産生された断片は第2の調製SDS−PAGEで精製され、選択された断片 はゲルから溶出されることを特徴とする、請求項1−6に記載の方法。
- 8.調製SDS−PAGEにより上皮腫瘍細胞からサイトケラチンを精製し、サ イトケラチン8、18および19に対応するバンドをゲルから溶出し、サイトケ ラチンを消化して10−50Kdのサイズ範囲の断片の混合物を産生することに よりサイトケラチン断片混合物は産生されることを特徴とする、サイトケラチン 断片混合物。
- 9.動物をサイトケラチン断片を含む溶液で免疫し、動物から該断片に対する抗 体を回収することを含む、サイトケラチン断片に対する抗体を産生する方法であ って、調製SDS−PAGEにより上皮腫瘍細胞からサイトケラチンを精製し、 サイトケラチン8、18および19に対応するバンドをゲルから溶出し、サイト ケラチンを消化して10−50Kdのサイズ範囲の断片の混合物を産生すること によりサイトケラチン断片を産生することを特徴とする、上記方法。
- 10.マウスをサイトケラチン断片を含む溶液で免疫し、該マウスの脾臓からリ ンパ球を回収し、該リンパ球をミエローマ細胞と融合させ、ハイブリドーマ細胞 をクローン化し増殖させ、単一クローンを安定化し確立することを含む、サイト ケラチン断片に対するモノクローナル抗体の産生方法であって、調製SDS−P AGEにより上皮腫瘍細胞からサイトケラチンを精製し、サイトケラチン8、1 8および19に対応するバンドをゲルから溶出し、サイトケラチンを消化して1 0−50Kdのサイズ範囲の断片の混合物を産生することによりサイトケラチン 断片を産生することを特徴とする、上記方法。
- 11.体液中の上皮起源の腫瘍を検出する免疫化学的試験キットであって、請求 項8の方法により産生されるサイトケラチン断片の混合物と、請求項10の方法 により産生される断片に対するモノクローナル抗体とを含むことを特徴とする、 上記キット。
- 12.上皮腫瘍の治療用の薬剤の調製のためのサイトケラチンまたは放射性同位 元素に結合した、請求項10により産生されるモノクローナル抗体の使用。
- 13.免疫組織学または免疫細胞学用の検出可能な標識物に結合した、請求項1 0の方法により産生されるモノクローナル抗体の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9003025A SE470273B (sv) | 1990-09-24 | 1990-09-24 | Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer |
SE9003025-5 | 1990-09-24 | ||
PCT/SE1991/000638 WO1992005197A1 (en) | 1990-09-24 | 1991-09-24 | Purification of cytokeratin fragments |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06501469A true JPH06501469A (ja) | 1994-02-17 |
JP3210666B2 JP3210666B2 (ja) | 2001-09-17 |
Family
ID=20380430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51612591A Expired - Fee Related JP3210666B2 (ja) | 1990-09-24 | 1991-09-24 | サイトケラチン断片の精製 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5728537A (ja) |
EP (1) | EP0550561B1 (ja) |
JP (1) | JP3210666B2 (ja) |
AT (1) | ATE191921T1 (ja) |
AU (1) | AU8546391A (ja) |
DE (1) | DE69132122T2 (ja) |
SE (1) | SE470273B (ja) |
WO (1) | WO1992005197A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541482A (ja) * | 1999-04-13 | 2002-12-03 | ヴィレックス アクチェンゲゼルシャフト | 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用 |
WO2005043166A1 (ja) * | 2003-10-30 | 2005-05-12 | Sysmex Corporation | 子宮腺癌の診断薬及び腺癌細胞の検出方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547928A (en) * | 1993-12-17 | 1996-08-20 | Matritech, Inc. | Methods and compositions for the detection of colon cancers |
ES2116906B1 (es) * | 1996-03-28 | 1999-03-01 | Consejo Superior Investigacion | Anticuerpo monocional pc2.27 asociado a tumores. |
US6168779B1 (en) * | 1997-09-16 | 2001-01-02 | The Regents Of The University Of California | Methods and kits for identifying ductal orifices |
US6890311B2 (en) | 1997-09-16 | 2005-05-10 | The Regents Of The University Of California | Methods for performing medical procedures within a breast duct |
ES2321351T3 (es) | 1997-09-30 | 2009-06-04 | Peviva Ab | Compuesto relacionados con apoptosis y su uso. |
WO2002055555A2 (en) * | 2000-12-21 | 2002-07-18 | Genzyme Corp | Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
DE10130985B4 (de) * | 2001-06-27 | 2004-03-18 | B.R.A.H.M.S Ag | Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente |
AU2002327704A1 (en) * | 2001-09-21 | 2003-04-01 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
US7306919B1 (en) * | 2001-10-31 | 2007-12-11 | Thornthwaite Jerry T | Antigen-antibody cancer recognition system |
AU2003207459A1 (en) * | 2002-01-03 | 2003-07-24 | The Scripps Research Institute | Cancer-associated epitope |
EP2041299A4 (en) * | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE |
KR101371127B1 (ko) | 2010-11-23 | 2014-03-10 | 한양대학교 산학협력단 | Her2와 결합하는 krt19 및 그 용도 |
SE538211C2 (sv) * | 2013-04-05 | 2016-04-05 | Idl Biotech Ab | Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0167616B1 (en) * | 1984-01-06 | 1995-07-26 | The Regents Of The University Of California | Cytokeratin tumor markers and assays for their detection |
US4727021A (en) * | 1984-06-01 | 1988-02-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cytokeratin |
US4722895A (en) * | 1984-09-25 | 1988-02-02 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Synthetic peptides for the production of specific keratin protein antibodies |
LU86654A1 (de) * | 1986-11-10 | 1988-06-13 | Progen Biotechnik Gmbh | Verfahren und vorrichtung zum auffinden von zellaesionen |
DE3815932A1 (de) * | 1988-01-26 | 1989-08-03 | Progen Biotechnik Gmbh | Verfahren zur identifizierung des ursprungs einer zellgewebsprobe |
EP0267355B1 (de) * | 1986-11-10 | 1991-09-18 | PROGEN Biotechnik GmbH | Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine |
PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
-
1990
- 1990-09-24 SE SE9003025A patent/SE470273B/sv not_active IP Right Cessation
-
1991
- 1991-09-24 WO PCT/SE1991/000638 patent/WO1992005197A1/en active IP Right Grant
- 1991-09-24 DE DE69132122T patent/DE69132122T2/de not_active Expired - Lifetime
- 1991-09-24 AT AT91917180T patent/ATE191921T1/de not_active IP Right Cessation
- 1991-09-24 JP JP51612591A patent/JP3210666B2/ja not_active Expired - Fee Related
- 1991-09-24 EP EP91917180A patent/EP0550561B1/en not_active Expired - Lifetime
- 1991-09-24 US US08/030,100 patent/US5728537A/en not_active Expired - Lifetime
- 1991-09-24 AU AU85463/91A patent/AU8546391A/en not_active Abandoned
-
1996
- 1996-06-19 US US08/666,835 patent/US5780032A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541482A (ja) * | 1999-04-13 | 2002-12-03 | ヴィレックス アクチェンゲゼルシャフト | 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用 |
WO2005043166A1 (ja) * | 2003-10-30 | 2005-05-12 | Sysmex Corporation | 子宮腺癌の診断薬及び腺癌細胞の検出方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0550561B1 (en) | 2000-04-19 |
EP0550561A1 (en) | 1993-07-14 |
DE69132122T2 (de) | 2001-01-11 |
DE69132122D1 (de) | 2000-05-25 |
ATE191921T1 (de) | 2000-05-15 |
SE9003025L (sv) | 1992-03-25 |
SE470273B (sv) | 1993-12-20 |
AU8546391A (en) | 1992-04-15 |
US5728537A (en) | 1998-03-17 |
WO1992005197A1 (en) | 1992-04-02 |
JP3210666B2 (ja) | 2001-09-17 |
US5780032A (en) | 1998-07-14 |
SE9003025D0 (sv) | 1990-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06501469A (ja) | サイトケラチン断片の精製 | |
US5866690A (en) | Detection of malignant tumor cells | |
CA2427643C (en) | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) | |
US20080118935A1 (en) | Methods and compositions for diagnosing neoplastic disease | |
JPH0249596A (ja) | ヒト前立腺上皮細胞の表面に特異的に反応するモノクローナル抗体 | |
JP2774491B2 (ja) | ヒトの消化器ガンに対するモノクローナル抗体 | |
US4486538A (en) | Detection of malignant tumor cells | |
JPS60501309A (ja) | 非小細胞肺癌に対する単クロ−ン抗体 | |
US6830896B2 (en) | Process for analyzing annexin-V in urine, and application thereof | |
JPS62253395A (ja) | 転移性ヒト腫瘍を確認する方法および組成物 | |
KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
JPH05500454A (ja) | 結腸癌のムチンエピトープに対するモノクローナル抗体を産生するハイブリドーマct43 | |
US11746146B2 (en) | Antibody composition specifically recognizing an immunogenic fragment peptide of EN2 protein | |
JPS61258173A (ja) | モノクロ−ナル抗体およびその製法ならびに用途 | |
US20040142400A1 (en) | High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody | |
JPS6378067A (ja) | 癌診断薬 | |
JPH1175839A (ja) | モノクローナル抗体、細胞株及びn1,n12−ジアセチルスペルミンの測定法 | |
JP4451784B2 (ja) | 前立腺癌腫瘍マーカー | |
US7569675B2 (en) | High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody | |
Bogoch et al. | Malignin, anti-malignin antibody and scantag | |
JPH0342572A (ja) | ラミニン測定試薬 | |
JPH08208698A (ja) | モノクローナル抗体 | |
JPS62297755A (ja) | 間質性肺炎診断用試薬 | |
JPH0921803A (ja) | 2型コラーゲンテロペプチドの測定方法 | |
JPH07206899A (ja) | がん発生蛋白28kDを認識する単クローン抗体及び該単クローン抗体を含有する診断試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070713 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080713 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080713 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090713 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090713 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100713 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110713 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |